Slingshot members are tracking this event:

FDA approves new dosage strength of Teva's (TEVA) buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 07, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Buprenorphine, Naloxone, Sublingual Tablets, Opioid Addiction